Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Invivyd, Inc. - Common Stock
(NQ:
IVVD
)
0.7698
-0.0002 (-0.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Invivyd, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
July 23, 2025
From
Invivyd
Via
GlobeNewswire
National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population
July 21, 2025
From
Invivyd
Via
GlobeNewswire
What to Expect from Invivyd's Earnings
May 14, 2025
Via
Benzinga
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
July 02, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
June 26, 2025
From
Invivyd
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 27, 2025
Via
Benzinga
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2
May 27, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
May 23, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
May 21, 2025
From
Invivyd
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 15, 2025
Via
Benzinga
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 15, 2025
From
Invivyd
Via
GlobeNewswire
Earnings Scheduled For May 15, 2025
May 15, 2025
Via
Benzinga
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy
May 14, 2025
From
Invivyd
Via
GlobeNewswire
There are notable gap-ups and gap-downs in today's session.
May 13, 2025
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via
Chartmill
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
May 13, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’
May 12, 2025
Invivyd unveiled a discovery program for a measles-targeted monoclonal antibody, responding to provider demand amid a lack of approved treatments or post-exposure options.
Via
Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
May 12, 2025
Via
Benzinga
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
May 12, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
May 08, 2025
From
Invivyd
Via
GlobeNewswire
Wednesday's session: top gainers and losers
May 07, 2025
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
What's Going On With Invivyd Stock On Monday?
April 21, 2025
Invivyd, Inc. (NASDAQ: IVVD) secures $30M loan facility with Silicon Valley Bank for future capital drawdowns and aims for near-term profitability.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 21, 2025
Via
Benzinga
Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank
April 21, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
March 26, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
March 20, 2025
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1
March 05, 2025
From
Invivyd
Via
GlobeNewswire
Top movers in Monday's session
February 24, 2025
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
These stocks are moving in today's session
February 24, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
February 24, 2025
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via
Chartmill
Wondering what's happening in today's pre-market session?
February 24, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.